Buyukbayram Mehmet Emin, Hannarici Zekeriya, Yilmaz Ali, Turhan Aykut, Caglar Alperen Akansel, Esdur Pınar Coban, Bilici Mehmet, Tekin Salim Basol
Department of Medical Oncology, Atatürk University Faculty of Medicine, Erzurum, 25100, Turkey.
Department of Medical Oncology, Nev Hospital, Sanliurfa, 63000, Turkey.
Lung Cancer Manag. 2024 May 16;13(1):LMT66. doi: 10.2217/lmt-2023-0014. eCollection 2024.
The tumor microenvironment of NSCLC with driver mutations, such as , and , is less inflammatory. This retrospective study included 38 patients with NSCLC driver mutations. The relationship between clinical and inflammatory markers concerning progression-free survival and overall survival was analyzed based on Kaplan-Meier curves. The mean age of the patients was 59.8 ± 11.9. Progression-free survival and overall survival were significantly longer in patients under 65 years of age and with low neutrophil-lymphocyte ratio, low systemic immune-inflammation index and high lymphocyte count (p < 0.05). Unlike tumor biology, peripheral inflammatory parameters, such as neutrophil-lymphocyte ratio, systemic immune-inflammation index and lymphocyte count may be associated with survival in NSCLC patients with driver mutations.
具有驱动基因突变（如 、 和 ）的非小细胞肺癌的肿瘤微环境炎症较轻。这项回顾性研究纳入了38例患有非小细胞肺癌驱动基因突变的患者。基于Kaplan-Meier曲线分析了与无进展生存期和总生存期相关的临床和炎症标志物之间的关系。患者的平均年龄为59.8±11.9岁。65岁以下、中性粒细胞与淋巴细胞比值低、全身免疫炎症指数低且淋巴细胞计数高的患者无进展生存期和总生存期明显更长（p<0.05）。与肿瘤生物学不同，外周炎症参数，如中性粒细胞与淋巴细胞比值、全身免疫炎症指数和淋巴细胞计数可能与患有驱动基因突变的非小细胞肺癌患者的生存期相关。
